Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.
Earnings for Prometheus Biosciences, Inc. (RXDX)
Earnings in 2023 (TTM): $-141,752,000
According to Prometheus Biosciences, Inc.'s latest financial reports the company's current earnings (TTM) are $-141,752,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Prometheus Biosciences, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-141,752,000 | $-141,752,000 |
| 2022 | $-90,195,000 | $-89,937,000 |
| 2021 | $-31,139,000 | $-39,253,000 |
| 2020 | $-16,729,000 | $-30,493,000 |
| 2017 | $-103,639,000 | $-103,639,000 |
| 2016 | $-92,458,000 | $-92,458,000 |
| 2015 | $-39,977,316 | $-39,989,646 |